{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:26:57Z","timestamp":1730870817442,"version":"3.28.0"},"reference-count":22,"publisher":"Rambam Health Corporation","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rambam Maimonides Med J"],"abstract":"<jats:p>Introduction: The second wave of coronavirus disease 2019 (COVID-19) led to the resurgence of opportunistic infections due to the injudicious use of steroids. Sinonasal mucormycosis was declared an epidemic in India during the pandemic. Mucormycosis was managed effectively by surgical debridement along with systemic amphotericin B. Currently, a resurgence of mucormycosis following initial treatment, in the form of fungal osteomyelitis of the frontal bone, is being seen in India.  Methods: This prospective study included 10 patients with fungal osteomyelitis of the frontal bone due to mucormycosis. All patients underwent surgical debridement of the sequestrum and involucrum, with systemic antifungal pharmacotherapy.  Results: The average duration of time until mucormycosis recurrence was 22 days following initial treatment (range 10\u201333 days). Patients presented with extracranial bossing following outer frontal cortex erosion (n=3), bicortical erosion (n=3), bifrontal involvement (n=2), dural involvement (n=3), and involvement of the brain parenchyma and prefrontal cortex (n=2). All cases underwent debridement of the entire sequestrous bone and involucrum until normal bone could be identified. The mean admission duration was 4 weeks (range 3\u20136 weeks). All treated patients are currently alive and without disease, confirmed by contrast-enhanced computed tomography.  Conclusion: Based on our experience, the successful treatment of fungal osteomyelitis due to mucormycosis requires a four-pronged approach: early detection, multidisciplinary management of comorbidities, surgical debridement of necrotic bone, and adequate systemic antifungal therapy.<\/jats:p>","DOI":"10.5041\/rmmj.10484","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T07:25:02Z","timestamp":1666855502000},"page":"e0025","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of Open Fronto-Facial Resection for Fungal Osteomyelitis of Frontal Bone"],"prefix":"10.5041","volume":"13","author":[{"name":"Department of Otolaryngology and Head Neck Surgery, All India Institute of Medical Sciences, Raipur, India","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupa","family":"Mehta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik Nagaraga","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Head and Neck Oncology, All India Institute of Medical Sciences, Raipur, India","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin M.","family":"Nagarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Director and CEO, All India Institute of Medical Sciences, Raipur, India","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Neurosurgery, All India Institute of Medical Sciences, Raipur, India","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badal","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Otolaryngology and Head Neck Surgery, All India Institute of Medical Sciences, Raipur, India","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"P","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Otolaryngology and Head Neck Surgery, All India Institute of Medical Sciences, Raipur, India","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2983","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Dyer O. Covid-19: delta infections threaten herd immunity vaccine strategy. BMJ 2021;374:n1933.","DOI":"10.1136\/bmj.n1933"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Bhogireddy R, Krishnamurthy V, Jabaris S SL, Pullaiah CP, Manohar S. Is mucormycosis an inevitable complication of Covid-19 in India? Braz J Infect Dis 2021;25:101597.","DOI":"10.1016\/j.bjid.2021.101597"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/tmi.13641","article-title":"COVID\u201019 and mucormycosis syndemic: double health threat to a collapsing healthcare system in India","volume":"26","author":"Rocha","year":"2021","unstructured":"3. Rocha ICN, Hasan MM, Goyal S, et al. COVID\u201019 and mucormycosis syndemic: double health threat to a collapsing healthcare system in India. Trop Med Int Health 2021;26:1016-18.","journal-title":"Trop Med Int Health"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.4103\/ijo.IJO_1165_21","article-title":"Code mucor: guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19","volume":"69","author":"Honavar","year":"2021","unstructured":"4. Honavar SG. Code mucor: guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J Ophthalmol 2021;69:1361-5.","journal-title":"Indian J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"106110","DOI":"10.1016\/j.ijsu.2021.106110","article-title":"2021:106031)","volume":"94","author":"MohanaSundaram","year":"2021","unstructured":"5. MohanaSundaram A, Thukani Sathanantham S, Chinchole V, Patil B, Velayutham R. Fostering a deeper understanding of COVID-19-associated mucormycosis - a commentary on \"The mucormycosis coinfection in the context of global COVID-19 outbreak: A fatal addition to the pandemic spectrum\" (Int. J. Surg. 2021:106031). Int J Surg 2021;94: 106110.","journal-title":"Int J Surg"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jaapos.2015.06.001","article-title":"Ophthalmic manifestations and outcomes after cavernous sinus thrombosis in children","volume":"19","author":"Frank","year":"2015","unstructured":"6. Frank GS, Smith JM, Davies BW, Mirsky DM, Hink EM, Durairaj VD. Ophthalmic manifestations and outcomes after cavernous sinus thrombosis in children. J AAPOS 2015;19:358-62.","journal-title":"J AAPOS"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/bmj.305.6859.913","article-title":"Low molecular weight heparin in prevention of perioperative thrombosis","volume":"305","author":"Leizorovicz","year":"1992","unstructured":"7. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992;305:913-20.","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Onyekwelu I, Yakkanti R, Protzer L, Pinkston CM, Tucker C, Seligson D. Surgical wound classification and surgical site infections in the orthopaedic patient. J Am Acad Orthop Surg Glob Res Rev 2017;1:e022.","DOI":"10.5435\/JAAOSGlobal-D-17-00022"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.4103\/ams.ams_23_16","article-title":"Mucormycosis of the frontal sinus: a rare case report and review","volume":"7","author":"Sahoo","year":"2017","unstructured":"9. Sahoo NK, Kulkarni V, Bhandari AK, Kumar A. Mucormycosis of the frontal sinus: a rare case report and review. Ann Maxillofac Surg 2017;7:120-3.","journal-title":"Ann Maxillofac Surg"},{"key":"ref9","unstructured":"10. Kaufman RS, Stone G. Osteomyelitis of frontal bone secondary to mucormycosis. N Y State J Med 1973; 73:1325-8. PMID: 4513739"},{"key":"ref10","unstructured":"11. Chan LL, Singh S, Jones D, Diaz Jr EM, Ginsberg LE. Imaging of mucormycosis skull base osteomyelitis. Am J Neuroradiol 2000;21:828-31. PMID: 10815656 PMCID: PMC7976772"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4103\/0975-5950.127663","article-title":"Necrosis of maxilla, nasal, and frontal bone secondary to extensive rhino-cerebral mucormycosis","volume":"4","author":"Verma","year":"2013","unstructured":"12. Verma A, Singh V, Jindal N, Yadav S. Necrosis of maxilla, nasal, and frontal bone secondary to extensive rhino-cerebral mucormycosis. Natl J Maxillofac Surg 2013;4:249-51.","journal-title":"Natl J Maxillofac Surg"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s00405-005-0919-0","article-title":"Rhinocerebral mucormycosis: pathways of spread","volume":"262","author":"SMS","year":"2005","unstructured":"13. Hosseini SMS, Borghei P. Rhinocerebral mucormycosis: pathways of spread. Eur Arch Otorhinolaryngol 2005;262:932-8.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.coms.2008.12.003","article-title":"Management of frontal sinus fractures","volume":"21","author":"Bell","year":"2009","unstructured":"14. Bell RB. Management of frontal sinus fractures. Oral Maxillofac Surg Clin North Am 2009;21:227-42.","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0030-6665(00)80008-0","article-title":"An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient","volume":"33","author":"Gillespie","year":"2000","unstructured":"15. Gillespie MB, O'Malley BW. An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient. Otolaryngol Clin North Am 2000;33:323-34.","journal-title":"Otolaryngol Clin North Am"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/myc.13334","article-title":"Mucormycosis in patients with COVID-19: a cross-sectional descriptive multicenter study from Iran","volume":"64","author":"Pakdel","year":"2021","unstructured":"16. Pakdel F, Ahmadikia K, Salehi M, et al. Mucormycosis in patients with COVID-19: a cross-sectional descriptive multicenter study from Iran. Mycoses 2021;64:1238-52.","journal-title":"Mycoses"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.anl.2009.09.001","article-title":"Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis","volume":"37","author":"Scheckenbach","year":"2010","unstructured":"17. Scheckenbach K, Cornely O, Hoffmann TK, et al. Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis. Auris Nasus Larynx 2010;37:322-8.","journal-title":"Auris Nasus Larynx"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Anaissie EJ, Shikhani AH. Rhinocerebral mucormycosis with internal carotid occlusion: report of two cases and review of the literature. Laryngoscope 1985;95:1107-13. PMID: 4033336","DOI":"10.1288\/00005537-198509000-00018"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Camara-Lemarroy CR, Gonz\u00e1lez-Moreno EI, Rodr\u00edguez-Guti\u00e9rrez R, et al. Clinical features and outcome of mucormycosis. Interdiscip Perspect Infect Dis 2014;2014:e562610.","DOI":"10.1155\/2014\/562610"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","unstructured":"20. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44:1289-97.","journal-title":"Clin Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/jof4030090","article-title":"Therapy of mucormycosis","volume":"4","author":"Sipsas","year":"2018","unstructured":"21. Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP. Therapy of mucormycosis. J Fungi (Basel) 2018;4:90.","journal-title":"J Fungi (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"20499361221084844","DOI":"10.1177\/20499361221084844","article-title":"Mucormycosis and COVID-19: manifestations of the central nervous system and the ocular system","volume":"9","author":"Polo Mart\u00ednez","year":"2022","unstructured":"22. Polo Mart\u00ednez MA, Campo Jim\u00e9nez RF, Castrill\u00f3n Lozano JA. Mucormycosis and COVID-19: manifestations of the central nervous system and the ocular system. Ther Adv Infect Dis 2022;9: 20499361221084844.","journal-title":"Ther Adv Infect Dis"}],"container-title":["Rambam Maimonides Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.rmmj.org.il\/userimages\/1465\/1\/PublishFiles\/1521Article.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:33:08Z","timestamp":1730813588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rmmj.org.il\/issues\/55\/articles\/1521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,27]]}},"URL":"https:\/\/doi.org\/10.5041\/rmmj.10484","relation":{},"ISSN":["2076-9172"],"issn-type":[{"type":"electronic","value":"2076-9172"}],"subject":[],"published":{"date-parts":[[2022,10,27]]}}}